IP Library Granted Patent US 8,853,397
Granted Patent B2
US 8,853,397 · App. 13/759,835 · Granted Oct 7, 2014

2,4-pyrimidinediamine compounds and their uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,853,397
App. No.
13/759,835
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Claims (17)

1. A compound according to Formula (I)

or a salt thereof, wherein:

one of R 2 and R 4 is a phenyl monosubstituted with (C1-C10)alkyl, —OR a optionally substituted with one R b group, —O—C(O)OR a , —O—(CH 2 ) m —C(O)OR a , —C(O)OR a , —O—(CH 2 ) m —NR c R c , —O—C(O)NR c R c , —O—(CH 2 ) m —C(O)NR c R c , —O—C(NH)NR c R c , —O—(CH 2 ) m —C(NH)NR c R c or —NH—(CH 2 ) m NR c R c ;

the other of R 2 and R 4 is a phenyl monosubstituted or disubstituted with R 8 ;

R 2 and R 4 are different;

R 5 is —NR c R c , fluoro, —CN, or (C1-C6) alkyl optionally substituted with one or more of the same or different R 8 groups;

each R 8 is independently R a or R b ;

each R a is H or (C1-C6) alkyl;

each R b is —OR a , —OCF 3 , halogen, —CF 3 , —CN, —NO 2 , —N 3 , —SO 2 NR c R c , —C(O)R a , —C(O)OR a , —C(O)NR c R c , —C(NH)NR c R c , —C(NR a )NR c R c , —C(NOH)R a , —C(NOH)NR c R c ;

each R c is independently R a or, alternatively, two R c are taken together with the nitrogen atom to which they are bonded to form a 5- to 8-membered cycloheteroalkyl or heteroaryl; and

each m is independently 1 or 2.

2. The compound of claim 1 , wherein R 5 is fluoro or (C1-C4) alkanyl optionally substituted with one or more of the same or different R 8 groups.

3. The compound of claim 2 , wherein each R b is independently —OR a , —OCF 3 , halogen, —CF 3 , —CN, —NO 2 , —N 3 , —SO 2 NR c R c , —C(O)R a , —C(O)OR a or —C(O)NR c R c .

4. The compound of claim 3 , wherein R 5 is fluoro or —CF 3 .

5. The compound of claim 4 , wherein each m is 1.

6. The compound of claim 5 , wherein R 5 is fluoro.

7. The compound of claim 1 , wherein R 2 is phenyl monosubstituted with —O—(CH 2 ) m —NR c R c .

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2014
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD G.; MOLINEAUX, SUSAN; HOLLAND, SACHA J.; CLOUGH, JEFFREY; KEIM, HOLGER; BHAMIDIPATI, SOMASEKHAR; SYLVAIN, CATHERINE; LI, HUI; ROSSI, ALEXANDER B.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 032833/0456 →